Rapid Response for Notification of Monkeypox Exposure, Exposure Risk Assessment and Stratification, and Symptom Monitoring - Simpson, Lynn A.; Macdonald, Kaitlin; Searle, Eileen F.; Shearer, Jennifer A.; Dimitrov, Dimitar; Foley, Daniel; Morales, Eduardo; Shenoy, Erica S. (medRxiv, 2022)
Objective Public health authorities recommend symptom monitoring of healthcare personnel (HCP) after defined exposures to Monkeypox (MPX). We report on the rapid development and implementation of mobile responsive survey solutions for notification of possible exposure, exposure risk assessment and stratification, and symptom monitoring.Setting Academic health center in Boston, Massachusetts, after admission of first diagnosed case of MPX in the United States during the current global outbreak.Participants Research Electronic Data Capture (REDCap) design and programmers, Infection Control, Occupational Health, and Emergency Preparedness specialists, and HCP with possible exposure to MPX.Interventions Design and deployment of Research Electronic Data Capture (REDCap) tools to identify HCP with possible exposure to MPX, perform exposure risk assessment and stratification for post-exposure prophylaxis (PEP), and conduct symptom monitoring during the exposure window. Project enhancements included dashboards for HCP tracking and SMS text reminders for symptom monitoring.Results Tools to support the contact tracing and exposure investigation were deployed within 24 hours of identification of a patient with suspected MPX, with the full suite in production within 4 days of confirmation of the diagnosis of MPX. Clinical follow up of HCP was integrated into the design, and real-time versioning allowed for adjustments leading to improvements in HCP symptom monitoring compliance and enhanced tracking.Conclusions During the current MPX outbreak, timely and comprehensive evaluation of potential HCP exposures is necessary but presents logistical challenges. Rapid development of MPX-specific solutions using REDCap enabled flexibility in design and approach, and integration of targeted clinical support enhanced functionality.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by US Assistant Secretary for Preparedness and Response (6 U3REP150548-05-08 to EFS and ESS). This work was conducted with support from Harvard Catalyst | The Harvard Clinical and Translational Science Center (National Center for Advancing Translational Sciences, National Institutes of Health Award UL1 TR002541) and financial contributions from Harvard University and its affiliated academic healthcare centers. The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard Catalyst, Harvard University and its affiliated academic healthcare centers, or the National Institutes of Health. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Mass General Brigham Human Research Affairs Office, which oversees the Mass General Brigham Institutional Review Boards (IRBs), has determined that the study does not meet the regulatory definition of human subjects research per 45CFR46.102(l).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript https://community.projectredcap.org/articles/128815/mgh-monkeypox-redcap-toolkit.html